Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

IL-23 inhibitors may help treat other skin conditions, but more research is needed.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Topical IKKα inhibitors may help prevent CCS tumours.

Risankizumab may help manage symptoms of dissecting cellulitis of the scalp.

Tofacitinib might be used to treat hair loss.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Baricitinib is effective and safe for treating severe alopecia areata.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Tofacitinib helped a woman regrow hair with no major side effects.

Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Cilostazol may help hair grow and could be a new treatment for hair loss.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Tacrolimus is a better option than cyclosporine due to fewer side effects.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Ruxolitinib cream may help treat severe hair loss in children.